217 related articles for article (PubMed ID: 37902294)
1. Late Onset of Rivaroxaban-Associated Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Agarwal M; Cummings K; Larsen B; Chopra M; Rodriguez-Pla A
J Investig Med High Impact Case Rep; 2023; 11():23247096231207689. PubMed ID: 37902294
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
3. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
5. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
6. Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults.
Stainer A; Rice A; Devaraj A; Barnett JL; Donovan J; Kokosi M; Nicholson AG; Cairns T; Wells AU; Renzoni EA
BMC Pulm Med; 2019 Oct; 19(1):185. PubMed ID: 31651292
[TBL] [Abstract][Full Text] [Related]
7. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
8. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.
Bensalem A; Mulleman D; Paintaud G; Azzopardi N; Gouilleux-Gruart V; Cornec D; Specks U; Ternant D
Clin Pharmacokinet; 2020 Apr; 59(4):519-530. PubMed ID: 31586310
[TBL] [Abstract][Full Text] [Related]
9. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
11. A Rare Case of Hydralazine-Induced Diffuse Alveolar Hemorrhage.
Xue A; Bernard A; Moreno V; Phillips L; Raff E
Cureus; 2023 Oct; 15(10):e47591. PubMed ID: 38022102
[TBL] [Abstract][Full Text] [Related]
12. Anti-neutrophil cytoplasmic antibodies predate symptom onset of ANCA-associated vasculitis. A case-control study.
Berglin E; Mohammad AJ; Dahlqvist J; Johansson L; Eriksson C; Sjöwall J; Rantapää-Dahlqvist S
J Autoimmun; 2021 Feb; 117():102579. PubMed ID: 33340843
[TBL] [Abstract][Full Text] [Related]
13. Acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody following cimetidine treatment: a case report.
Morimoto K; Kanzaki G; Niikura T; Koike K; Matsuo N; Maruyama Y; Tsuboi N; Yokoo T
BMC Nephrol; 2021 Aug; 22(1):294. PubMed ID: 34461843
[TBL] [Abstract][Full Text] [Related]
14. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
McClure ME; Wason J; Gopaluni S; Tieu J; Smith RM; Jayne DR; Jones RB
J Clin Rheumatol; 2019 Aug; 25(5):217-223. PubMed ID: 30896460
[TBL] [Abstract][Full Text] [Related]
17. Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10 Years of Hydralazine Use.
Russe-Russe JR; Pellegrini JR; Alvarez-Betancourt A; Munshi RF; Anand P
Cureus; 2021 Oct; 13(10):e18974. PubMed ID: 34820229
[TBL] [Abstract][Full Text] [Related]
18. Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.
Muto R; Inagaki K; Sato N; Sameshima T; Nagakura Y; Baba S; Kato N; Maruyama S; Akahori T
Intern Med; 2020 Dec; 59(24):3187-3193. PubMed ID: 32788533
[TBL] [Abstract][Full Text] [Related]
19. [Anti-neutrophil cytoplasmic antibodies-associated vasculitis with lung hemorrhage in the patient on maintenance haemodialysis: a case report].
Ding JX; Wang M
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):915-918. PubMed ID: 29045980
[TBL] [Abstract][Full Text] [Related]
20. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
